# Pfizer Inc.  Share Price Target ‘$31.55’, now 11.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.share-price-target-31.55-now-11.3-upside-potential/4121164740
- Published: 2024-07-12T13:43:04+01:00
- Author: Charlotte Edwards

**Pfizer Inc.** with ticker code (PFE) have now 22 market analysts covering the 
stock. The analyst consensus now points to a rating of ‘buy’. The target price High/
Low ranges between $45.00 and $27.00 suggesting an average analyst share price target
price of $31.55. (at the time of writing). Given that the stocks previous close 
was at $28.35 and the analysts are correct then there would likely be a percentage
uptick in value of 11.3%. The 50 day moving average now sits at $28.15 while the
200 day moving average is $28.59. The market cap for the company is 162.40B. The
stock price for the company is currently $28.66 USD

 The potential market cap would be $180,735,835,062 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $9.72 and
a 0.93% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on: